NASDAQ: GNFTGenfit Sa Stock
$3.60-0.10 (-2.7%)
Updated Jan 24, 2025
GNFT Price
$3.60
Fair Value Price
N/A
Market Cap
$179.66M
52 Week Low
$3.35
52 Week High
$6.42
P/E
7.27x
P/B
1.68x
P/S
1.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$92.31M
Earnings
$23.95M
Gross Margin
100%
Operating Margin
32.64%
Profit Margin
26.5%
Debt to Equity
1
Operating Cash Flow
-$45M
Beta
0.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GNFT Overview
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GNFT's potential to beat the market
- GNFT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GNFT
RankedUnranked of 555
RankedUnranked of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.17 | A | |
| $122.04 | A | |
| $2.96 | A |
Be the first to know about important GNFT news, forecast changes, insider trades & much more!
GNFT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GNFT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GNFT is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GNFT is good value based on its earnings relative to its share price (7.27x), compared to the US market average (30.33x)
P/E vs Market Valuation
GNFT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more GNFT due diligence checks available for Premium users.
Valuation
GNFT fair value
Fair Value of GNFT stock based on Discounted Cash Flow (DCF)
Price
$3.60
Fair Value
-$4.67
Undervalued by
177.03%
GNFT is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GNFT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
7.27x
Industry
-188.16x
Market
30.33x
GNFT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GNFT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
GNFT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.68x
Industry
5.04x
GNFT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GNFT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GNFT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GNFT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$209.4M
Liabilities
$104.7M
Debt to equity
1
GNFT's short-term assets ($149.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNFT's short-term assets ($149.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNFT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GNFT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GNFT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GNFT vs Biotech Stocks
Genfit Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.